Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 32Recruiting 19Terminated 12Active not recruiting 10Unknown 5Withdrawn 3Suspended 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Oligometastatic Prostate Carcinoma 1Oligo-metastatic Prostate Carcinoma 1Neoplasms 1Metastatic Hormone-Sensitive Prostate Cance 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Androgen Antagonists 9darolutamide 6Magnetic Resonance Spectroscopy 6enzalutamide 5apalutamide 5Docetaxel 5Specimen Handling 4Radiotherapy 4Abiraterone Acetate 4Prednisone 3Electroacupuncture 3Brachytherapy 3pembrolizumab 2Standard of Care 2Resistance Training 2Radiosurgery 2Radiation 2Pluvicto 2Interviews as Topic 2Gonadotropin-Releasing Hormone 2Glutamate Carboxypeptidase II 2Bone Density 2Absorptiometry, Photon 2testosterone 17 beta-cypionate 1relugolix 1perflutren 1olaparib 1luprolide acetate gel depot 1fluciclovine F-18 1fezolinetant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Prostatic Neoplasms × abiraterone × Clear all
NCT07620574 2026-06-02

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Exelixis

Phase 3 Not yet recruiting
5,000 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡